Onk Therapeutics Announces $21.5M Series A Financing To Advance Pipeline Of Next-Generation Optimally Engineered Off-The-Shelf Nk Cell Therapies

Jan 06, 2022•over 3 years ago

Amount Raised

$21.5 Million

Round Type

series a

Description

ONK Therapeutics, an innovative NK cell therapy platform company, today announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.

Onk Therapeutics Announces $21.5M Series A Financing To Advance Pipeline Of Next-Generation Optimally Engineered Off-The-Shelf Nk Cell Therapies

Description

Company Information

Funding Insights

Onk Therapeutics Announces $21.5M Series A Financing To Advance Pipeline Of Next-Generation Optimally Engineered Off-The-Shelf Nk Cell Therapies

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information